<DOC>
	<DOCNO>NCT01308762</DOCNO>
	<brief_summary>To evaluate safety tolerability intradermal injection IMM-101 ( Heat-killed Mycobacterium obuense ) melanoma cancer patient .</brief_summary>
	<brief_title>A Clinical Study , Evaluate Safety Tolerability Intradermal IMM-101 Adult Melanoma Cancer Patients</brief_title>
	<detailed_description>The propose study first-in-man , placebo-controlled , dose escalation trial evaluate safety tolerability three different dos IMM-101 administer intradermally melanoma patient . Additionally , study aim characterize local response vaccine order delineate unexpected / unacceptable local reaction indicative appropriate immunological response patient group .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>confirm diagnosis disease free stage III stage IV melanoma ( without metastasis ) stable disease ( metastasis ) receive treatment willing use effective contraception duration study able comply requirement complete diary card Pregnant lactating female Major surgery within 14 day precede screen visit Suspicion previous infection mycobacteria include previous tuberculosis ( TB ) prophylaxis Treatment another investigational medicinal product within last 30 day prior screen visit Previous treatment M. vaccae Exposure Bacille Calmette Gu√©rin vaccine ( BCG ) within last 12 month Concurrent us drug likely reduce inflammation local injection site dampen/modulate immune system Depot injection corticosteroid within 6 week screen visit chronic systemic corticosteroid 2 week prior screen visit Ongoing treatment radiotherapy , cytotoxic chemotherapy chemotherapy last 30 day prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>